Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458120 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00458120 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants.
The verdict
NCT00458120, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Dengue fever, which is caused by dengue viruses, is a major health problem in subtropical regions of the world. There are four different forms (serotypes) of dengue virus that can cause dengue fever. The purpose of this study is to determine the safety and immune response to a vaccine containing a particular dengue serotype when an individual has been previously vaccinated with a different dengue serotype.
Interventions
- BIOLOGICAL rDEN1delta30
- BIOLOGICAL rDEN2/4delta30(ME)
- BIOLOGICAL Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458120
The ClinicalTrials.gov registry entry for NCT00458120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rDEN1delta30 is the first listed.
NCT00458120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458120 about?
NCT00458120 is a clinical study titled "Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus". Dengue fever, which is caused by dengue viruses, is a major health problem in subtropical regions of the world. There are four different forms (serotypes) of dengue virus that can cause dengue fever. The purpose of this study is to determine the safety and immune response to a vaccine containing a p...
What is the current status of trial NCT00458120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00458120?
The interventions under investigation include: rDEN1delta30 (BIOLOGICAL), rDEN2/4delta30(ME) (BIOLOGICAL), Placebo to rDEN1delta30 or rDEN2/4delta30(ME) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00458120?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.